Advances in bronchopulmonary dysplasia

Expert Review of Respiratory Medicine

Volumn 8, Issue 3, 2014, Pages 327-338

  Strueby, Lannae ^a   Thébaud, Bernard ^b,c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

aging; bronchopulmonary dysplasia; corticosteroids; inflammation; lung injury; mechanical ventilation; nitric oxide; prematurity; stem cells; vitamin A

Indexed keywords

CAFFEINE; CORTICOSTEROID; DEXAMETHASONE; HYDROCORTISONE; INOSITOL; MEPREDNISONE; METHYLXANTHINE; MONTELUKAST; NITRIC OXIDE; RETINOL;

ARTIFICIAL VENTILATION; CORTICOSTEROID THERAPY; DISEASE COURSE; FOLLOW UP; HEALTH CARE COST; HUMAN; INTERMITTENT POSITIVE PRESSURE VENTILATION; INTUBATION; LUNG DYSPLASIA; LUNG FUNCTION; MESENCHYMAL STEM CELL TRANSPLANTATION; MORBIDITY; MORTALITY; NONHUMAN; PATENT DUCTUS ARTERIOSUS; PATHOGENESIS; POSITIVE END EXPIRATORY PRESSURE; PREMATURITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION; VOLUME TARGETED VENTILATION; BRONCHOPULMONARY DYSPLASIA; INCIDENCE; NONINVASIVE VENTILATION; PATHOPHYSIOLOGY; STEM CELL TRANSPLANTATION;

ADRENAL CORTEX HORMONES; BRONCHOPULMONARY DYSPLASIA; HUMANS; INCIDENCE; NONINVASIVE VENTILATION; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 84901001814     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/17476348.2014.899907     Document Type: Review

References (118)

1. Blencowe H, Cousens S, Oestergaard MZ, et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet 2012;379(9832): 2162-72
2. Lee SK, Ye XY, Singhal N, et al. Higher altitude and risk of bronchopulmonary dysplasia among preterm infants. Am J Perinatol 2013;30(7):601-6
3. National Heart, Lung, and Blood Institute. Early Treatment Prevents Lasting Breathing Problems in Some Premature Babies. Available from: http://www.nhlbi.nih.gov/news/press-releases/2006/early-treatmentprevents- lasting-breathing-problems-in-somepremature- babies.html
4. Northway WH Jr, Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med 1967; 276(7): 357-68.
5. Shennan AT, Dunn MS, Ohlsson A, et al. Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. Pediatrics 1988;82(4):527-32
6. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001;163(7):1723-9
7. Ehrenkranz RA, Walsh MC, Vohr BR, et al. Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. Pediatrics 2005;116(6):1353-60
8. Walsh MC, Wilson-Costello D, Zadell A, et al. Safety, reliability, and validity of a physiologic definition of bronchopulmonary dysplasia. J Perinatol 2003;23(6):451-6
9. Walsh MC, Yao Q, Gettner P, et al. Impact of a physiologic definition on bronchopulmonary dysplasia rates. Pediatrics 2004;114(5):1305-11
10. Van Marter LJ. Epidemiology of bronchopulmonary dysplasia. Semin Fetal Neonatal Med 2009;14(6):358-66
11. Carraro S, Filippone M, Da Dalt L, et al. Bronchopulmonary dysplasia: the earliest and perhaps the longest lasting obstructive lung disease in humans. Early Hum Dev 2013;89(Suppl 3):S3-5
12. Berkelhamer SK, Mestan KK, Steinhorn RH. Pulmonary hypertension in bronchopulmonary dysplasia. Semin Perinatol 2013;37(2):124-31
13. Schmidt B, Asztalos EV, Roberts RS, et al. Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms. JAMA 2003;289(9):1124-9
14. Walsh MC, Morris BH, Wrage LA, et al. Extremely low birthweight neonates with protracted ventilation: mortality and 18-month neurodevelopmental outcomes. J Pediatr 2005;146(6):798-804
15. Natarajan G, Pappas A, Shankaran S, et al. Outcomes of extremely low birth weight infants with bronchopulmonary dysplasia: impact of the physiologic definition. Early Hum Dev 2012;88(7):509-15
16. Mourani PM, Abman SH. Pulmonary vascular disease in bronchopulmonary dysplasia: pulmonary hypertension and beyond. Curr Opin Pediatr 2013;25(3): 329-37
17. Bhandari A, McGrath-Morrow S. Long-term pulmonary outcomes of patients with bronchopulmonary dysplasia. Semin Perinatol 2013;37(2):132-7
18. Gunville CF, Sontag MK, Stratton KA, et al. Scope and impact of early and late preterm infants admitted to the PICU with respiratory illness. J Pediatr 2010;157(2): 209-14; e1
19. Vom Hove M, Prenzel F, Uhlig HH, Robel-Tillig E. Pulmonary outcome in former preterm, very low birth weight children with bronchopulmonary dysplasia: a case-control follow-up at school age. J Pediatr 2014;164(1):40-5; e4
20. Fawke J, Lum S, Kirkby J, et al. Lung function and respiratory symptoms at 11 years in children born extremely preterm: the EPICure study. Am J Respir Crit Care Med 2010;182(2):237-45
21. Welsh L, Kirkby J, Lum S, et al. The EPICure study: maximal exercise and physical activity in school children born extremely preterm. Thorax 2010;65(2): 165-72
22. Clemm H, Roksund O, Thorsen E, et al. Aerobic capacity and exercise performance in young people born extremely preterm. Pediatrics 2012;129(1):e97-e105
23. Wong PM, Lees AN, Louw J, et al. Emphysema in young adult survivors of moderate-to-severe bronchopulmonary dysplasia. Eur Respir J 2008;32(2):321-8
24. Narayanan M, Beardsmore CS, Owers-Bradley J, et al. Catch-up alveolarization in ex-preterm children: evidence from (3)He magnetic resonance. Am J Respir Crit Care Med 2013;187(10): 1104-9
25. Baraldi E, Filippone M. Chronic lung disease after premature birth. N Engl J Med 2007;357(19):1946-55
26. Shah PS, Sankaran K, Aziz K, et al. Outcomes of preterm infants <29 weeks gestation over 10-year period in Canada: a cause for concern? J Perinatol 2012;32(2): 132-8.
27. Jobe AH. What is BPD in 2012 and what will BPD become? Early Hum Dev 2012; 88(Suppl 2):S27-8.
28. Fanaroff AA, Hack M, Walsh MC. The NICHD neonatal research network: changes in practice and outcomes during the first 15 years. Semin Perinatol 2003;27(4): 281-7
29. Payne NR, Finkelstein MJ, Liu M, et al. NICU practices and outcomes associated with 9 years of quality improvement collaboratives. Pediatrics 2010;125(3): 437-46
30. Tommiska V, Heinonen K, Lehtonen L, et al. No improvement in outcome of nationwide extremely low birth weight infant populations between 1996-1997 and 1999-2000. Pediatrics 2007;119(1): 29-36
31. Lee SK, McMillan DD, Ohlsson A, et al. Variations in practice and outcomes in the Canadian NICU network: 1996-1997. Pediatrics 2000;106(5):1070-9
32. Doyle LW, Ehrenkranz RA, Halliday HL. Dexamethasone treatment in the first week of life for preventing bronchopulmonary dysplasia in preterm infants: a systematic review. Neonatology 2010;98(3):217-24
33. Ghanta S, Tropea Leeman K, Christou H. An update on pharmacologic approaches to bronchopulmonary dysplasia. Semin Perinatol 2013;37(2):115-23
34. Zhao J, Gonzalez F, Mu D. Apnea of prematurity: from cause to treatment. Eur J Pediatr 2011;170(9):1097-105
35. Henderson-Smart DJ, Davis PG. Prophylactic methylxanthines for endotracheal extubation in preterm infants. Cochrane Database Syst Rev 2010(12): CD000139
36. Schmidt B, Roberts RS, Davis P, et al. Caffeine therapy for apnea of prematurity. N Engl J Med 2006; 354(20): 2112-21.
37. Davis PG, Schmidt B, Roberts RS, et al. Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups. J Pediatr 2010;156(3):382-7
38. Schmidt B, Anderson PJ, Doyle LW, et al. Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity. JAMA 2012;307(3):275-82
39. Demauro SB, Dysart K, Kirpalani H. Stopping the swinging pendulum of postnatal corticosteroid use. J Pediatr 2014; 164(1):9-11
40. Halliday HL, Ehrenkranz RA, Doyle LW. Early (<8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2010 (1):CD001146
41. Nixon PA, Washburn LK, Schechter MS, O'Shea TM. Follow-up study of a randomized controlled trial of postnatal dexamethasone therapy in very low birth weight infants: effects on pulmonary outcomes at age 8 to 11 years. J Pediatr 2007; 150(4): 345-50
42. Yeh TF, Lin YJ, Lin HC, et al. Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med 2004;350(13):1304-13
43. O'Shea TM, Washburn LK, Nixon PA, Goldstein DJ. Follow-up of a randomized, placebo-controlled trial of dexamethasone to decrease the duration of ventilator dependency in very low birth weight infants: neurodevelopmental outcomes at 4 to 11 years of age. Pediatrics 2007;120(3): 594-602
44. Jefferies AL. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Paediatr Child Health 2012;17(10):573-4
45. Halliday HL, Ehrenkranz RA, Doyle LW. Late (>7 days) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev 2009(1): CD001145
46. Watterberg KL; American Academy of Pediatrics. Committee on Fetus and Newborn. Policy statement-postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia. Pediatrics 2010;126(4): 800-8
47. DeCastro M, El-Khoury N, Parton L, et al. Postnatal betamethasone vs dexamethasone in premature infants with bronchopulmonary dysplasia: a pilot study. J Perinatol 2009; 29(4):297-304
48. Andre P, Thebaud B, Odievre MH, et al. Methylprednisolone, an alternative to dexamethasone in very premature infants at risk of chronic lung disease. Intensive Care Med 2000;26(10):1496-500
49. Parikh NA, Kennedy KA, Lasky RE, et al. Pilot randomized trial of hydrocortisone in ventilator-dependent extremely preterm infants: effects on regional brain volumes. J Pediatr 2013;162(4):685-90; e1
50. Kersbergen KJ, de Vries LS, van Kooij BJM, et al. Hydrocortisone Treatment for Bronchopulmonary Dysplasia and Brain Volumes in Preterm Infants. J Pediatr 2013; 163(3):666-71; e1
51. Inder TE, Benders M. Postnatal Steroids in the Preterm Infant-the Good, the Ugly, and the Unknown. J Pediatr 2013;162(4): 667-70
52. Doyle LW, Ehrenkranz RA, Halliday HL. Postnatal hydrocortisone for preventing or treating bronchopulmonary dysplasia in preterm infants: a systematic review. Neonatology 2010;98(2):111-17
53. Watterberg KL, Gerdes JS, Cole CH, et al. Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. Pediatrics 2004;114(6): 1649-57
54. Onland W, Offringa M, Cools F, et al. Systemic hydrocortisone to prevent bronchopulmonary dysplasia in preterm infants (the SToP-BPD study); a multicenter randomized placebo controlled trial. BMC Pediatr 2011;11:102
55. Kirpalani H, Millar D, Lemyre B, et al. A trial comparing noninvasive ventilation strategies in preterm infants. N Engl J Med 2013;369(7):611-20
56. Morley CJ, Davis PG, Doyle LW, et al. Nasal CPAP or intubation at birth for very preterm infants. N Engl J Med 2008; 358(7):700-8
57. SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network. Finer NN, Carlo WA, et al. Early CPAP versus surfactant in extremely preterm infants. N Engl J Med 2010;362(21):1970-9
58. Sandri F, Plavka R, Ancora G, et al. Prophylactic or early selective surfactant combined with nCPAP in very preterm infants. Pediatrics 2010;125(6):e1402-9
59. Dunn MS, Kaempf J, de Klerk A, et al. Randomized trial comparing 3 approaches to the initial respiratory management of preterm neonates. Pediatrics 2011;128(5): e1069-76
60. Schmolzer GM, Kumar M, Pichler G, et al. Non-invasive versus invasive respiratory support in preterm infants at birth: systematic review and meta-analysis. BMJ 2013;347:f5980
61. Stevens TP, Harrington EW, Blennow M, Soll RF. Early surfactant administration with brief ventilation vs. selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome. Cochrane Database Syst Rev 2007(4):CD003063
62. Rojas-Reyes MX, Morley CJ, Soll R. Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2012; 3: CD000510
63. Tang S, Zhao J, Shen J, et al. Nasal intermittent positive pressure ventilation versus nasal continuous positive airway pressure in neonates: a systematic review and meta-analysis. Indian Pediatr 2013; 50(4):371-6
64. Peng W, Zhu H, Shi H, Liu E. Volume-targeted ventilation is more suitable than pressure-limited ventilation for preterm infants: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed 2014;99(2):F158-65
65. Wheeler KI, Klingenberg C, Morley CJ, Davis PG. Volume-targeted versus pressure-limited ventilation for preterm infants: a systematic review and meta-analysis. Neonatology 2011;100(3): 219-27
66. Saugstad OD, Aune D. Optimal oxygenation of extremely low birth weight infants: a meta-analysis and systematic review of the oxygen saturation target studies. Neonatology 2013;105(1):55-63
67. Saugstad OD, Ramji S, Soll RF, Vento M. Resuscitation of newborn infants with 21 or 100% oxygen: an updated systematic review and meta-analysis. Neonatology 2008;94(3): 176-82
68. Kapadia VS, Chalak LF, Sparks JE, et al. Resuscitation of preterm neonates with limited versus high oxygen strategy. Pediatrics 2013;132(6):e1488-96
69. Vento M, Moro M, Escrig R, et al. Preterm resuscitation with low oxygen causes less oxidative stress, inflammation, and chronic lung disease. Pediatrics 2009;124(3):e439-49
70. Sweet DG, Carnielli V, Greisen G, et al. European consensus guidelines on the management of neonatal respiratory distress syndrome in preterm infants-2013 update. Neonatology 2013;103(4):353-68
71. Clyman RI. The role of patent ductus arteriosus and its treatments in the development of bronchopulmonary dysplasia. Semin Perinatol 2013;37(2): 102-7
72. Kugelman A, Durand M. A comprehensive approach to the prevention of bronchopulmonary dysplasia. Pediatr Pulmonol 2011;46(12):1153-65
73. Clyman R, Cassady G, Kirklin JK, et al. The role of patent ductus arteriosus ligation in bronchopulmonary dysplasia: reexamining a randomized controlled trial. J Pediatr 2009;154(6):873-6
74. Peliowski A; Canadian Paediatric Society, Fetus and Newborn Committee. Inhaled nitric oxide use in newborns. Paediatr Child Health 2012;17(2):95-100
75. Afshar S, Gibson LL, Yuhanna IS, et al. Pulmonary NO synthase expression is attenuated in a fetal baboon model of chronic lung disease. Am J Physiol Lung Cell Mol Physiol 2003;284(5):L749-58
76. Raffay TM, Martin RJ, Reynolds JD. Can nitric oxide-based therapy prevent bronchopulmonary dysplasia? Clin Perinatol 2012;39(3):613-38.
77. Ghanta S, Tropea Leeman K, Christou H. An update on pharmacologic approaches to bronchopulmonary dysplasia. Semin Perinatol 2013;37(2):115-23
78. Barrington KJ, Finer N. Inhaled nitric oxide for respiratory failure in preterm infants. Cochrane Database Syst Rev 2010(12): CD000509
79. Donohue PK, Gilmore MM, Cristofalo E, et al. Inhaled nitric oxide in preterm infants: a systematic review. Pediatrics 2011; 127(2): e414-22
80. Cole FS, Alleyne C, Barks JD, et al. NIH Consensus Development Conference statement: inhaled nitric-oxide therapy for premature infants. Pediatrics 2011;127(2): 363-9
81. Clinicaltrials.gov. Examining the Use of Non-Invasive Inhaled Nitric Oxide to Reduce Chronic Lung Disease in Premature Newborns, National Heart, Lung and Blood Institute. Available from: http://clinicaltrials. gov/ct2/show/NCT00955487?term=nitric +oxide+AND+bronchopulmonary +dysplasia&rank=6
82. Clinicaltrials.gov. Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants, INO Therapeutics. Available from: http://clinicaltrials.gov/ct2/show/NCT00931632?term=nitric+oxide +AND+bronchopulmonary +dysplasia&rank=2
83. Levesque BM, Kalish LA, LaPierre J, et al. Impact of implementing 5 potentially better respiratory practices on neonatal outcomes and costs. Pediatrics 2011; 128(1): e218-26
84. Clinicaltrials.gov. The efficacy and safety of montelukast sodium in the prevention of bronchopulmonary dysplasia, Ajou University School of Medicine. Available from: http://clinicaltrials.gov/ct2/show/NCT01717625?term= montelukast+in+very +low+birth+weight+infants&rank=2
85. Howlett A, Ohlsson A, Plakkal N. Inositol for respiratory distress syndrome in preterm infants. Cochrane Database Syst Rev 2012; 3: CD000366
86. Clinicaltrials.gov. Multidose pharmacokinetics and dose ranging of inositol in premature infants (INS-2), Eunice Kennedy Shriver National Institute of Child Health and Human Development. Available from: http://clinicaltrials. gov/ct2/show/NCT01030575?term=inositol+AND +BPD&rank=1
87. Mactier H, Weaver LT. Vitamin A and preterm infants: what we know, what we don't know, and what we need to know. Arch Dis Child Fetal Neonatal Ed 2005; 90(2): F103-8
88. Darlow BA, Graham PJ. Vitamin A supplementation to prevent mortality and short- and long-term morbidity in very low birthweight infants. Cochrane Database Syst Rev 2011(10):CD000501
89. James ML, Ross AC, Nicola T, et al. VARA attenuates hyperoxia-induced impaired alveolar development and lung function in newborn mice. Am J Physiol Lung Cell Mol Physiol 2013; 304(11): L803-12
90. Tyson JE, Wright LL, Oh W, et al. Vitamin A supplementation for extremelylow- birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med 1999;340(25):1962-8
91. Ambalavanan N, Tyson JE, Kennedy KA, et al. Vitamin A supplementation for extremely low birth weight infants: outcome at 18 to 22 months. Pediatrics 2005;115(3): e249-54
92. Moreira A, Caskey M, Fonseca R, et al. Impact of providing vitamin A to the routine pulmonary care of extremely low birth weight infants. J Matern Fetal Neonatal Med 2012;25(1):84-8
93. Meyer S, Gortner L; NeoVitaA Trial Investigators. Early postnatal additional high-dose oral vitamin a supplementation versus placebo for 28 Days for preventing bronchopulmonary dysplasia or death in extremely low birth weight infants. Neonatology 2014;105(3):182-8
94. Berggren E, Liljedahl M, Winbladh B, et al. Pilot study of nebulized surfactant therapy for neonatal respiratory distress syndrome. Acta Paediatr 2000;89(4):460-4
95. Abdel-Latif ME, Osborn DA. Nebulised surfactant in preterm infants with or at risk of respiratory distress syndrome. Cochrane Database Syst Rev 2012;10:CD008310
96. Dargaville PA, Aiyappan A, De Paoli AG, et al. Minimally-invasive surfactant therapy in preterm infants on continuous positive airway pressure. Arch Dis Child Fetal Neonatal Ed 2013;98(2):F122-6
97. Lista G, Fontana P, Castoldi F, et al. Does sustained lung inflation at birth improve outcome of preterm infants at risk for respiratory distress syndrome? Neonatology 2011;99(1):45-50.
98. Hillman NH, Kemp MW, Noble PB, et al. Sustained inflation at birth did not protect preterm fetal sheep from lung injury. Am J Physiol Lung Cell Mol Physiol 2013; 305(6):L446-53
99. Dani C, Lista G, Pratesi S, et al. Sustained lung inflation in the delivery room in preterm infants at high risk of respiratory distress syndrome (SLI STUDY): study protocol for a randomized controlled trial. Trials 2013;14:67
100. Assessment of Lung Aeration at Birth, University of Alberta, Canada. Available from: http://clinicaltrials.gov/ct2/show/NCT01739114?term= sustained+inflation +AND+bronchopulmonary +dysplasia&rank=1
101. Colaizy TT, Younis UM, Bell EF, Klein JM. Nasal high-frequency ventilation for premature infants. Acta Paediatr 2008; 97(11): 1518-22
102. Non-invasive Ventilation for Extubation Success in Infants Less Than 1,500 Grams (NOVEL), Mount Sinai Hospital, Canada. Available from: http://clinicaltrials.gov/ct2/show/NCT02051491?term=non-invasive +high+frequency&rank=1
103. Tolerance to nHFPV Versus nCPAP in Neonatal Respiratory Distress (TONIPEP), University Hospital, Bordeaux. Available from: http://clinicaltrials. gov/ct2/show/NCT02030691?term=non-invasive+high +frequency&rank=2
104. van Haaften T, Byrne R, Bonnet S, et al. Airway delivery of mesenchymal stem cells prevents arrested alveolar growth in neonatal lung injury in rats. Am J Respir Crit Care Med 2009; 180(11): 1131-42
105. Blaisdell CJ, Gail DB, Nabel EG. National Heart, Lung, and Blood Institute perspective: lung progenitor and stem cells- gaps in knowledge and future opportunities. Stem Cells 2009;27(9):2263-70
106. O'Reilly M, Thébaud B. Using cell-based strategies to break the link between bronchopulmonary dysplasia and the development of chronic lung disease in later life. Pulm Med 2013;2013:874161
107. Borghesi A, Cova C, Gazzolo D, Stronati M. Stem cell therapy for neonatal diseases associated with preterm birth. J Clin Neonatol 2013;2(1):1-7
108. Bernardo ME, Pagliara D, Locatelli F. Mesenchymal stromal cell therapy: a revolution in Regenerative Medicine? Bone Marrow Transplant 2012;47(2): 164-71.
109. Aslam M, Baveja R, Liang OD, et al. Bone marrow stromal cells attenuate lung injury in a murine model of neonatal chronic lung disease. Am J Respir Crit Care Med 2009; 180(11):1122-30
110. Tropea KA, Leder E, Aslam M, et al. Bronchioalveolar stem cells increase after mesenchymal stromal cell treatment in a mouse model of bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol 2012;302(9):829-37
111. Zhang H, Fang J, Su H, et al. Bone marrow mesenchymal stem cells attenuate lung inflammation of hyperoxic newborn rats. Pediatr Transplant 2012;16(6):589-98
112. Fung ME, Thebaud B. Stem cell-based therapy for neonatal lung disease: it is in the juice. Pediatr Res 2014;75:2-7
113. Pierro M, Ionescu L, Montemurro T, et al. Short-term, long-term and paracrine effect of human umbilical cord-derived stem cells in lung injury prevention and repair in experimental bronchopulmonary dysplasia. Thorax 2013;68(5):475-84
114. Chang YS, Choi SJ, Sung DK, et al. Intratracheal transplantation of human umbilical cord blood-derived mesenchymal stem cells dose-dependently attenuates hyperoxia-induced lung injury in neonatal rats. Cell Transplant 2011;20(11-12): 1843-54
115. Ahn S, Chang Y, Kim E, et al. Human umbilical cord blood derived mensenchymal stem cells transplantation for bronchopulmonary dysplasia: results of a phase I dose escalation clinical study. Pediatric Academic Societies Annual Meeting. Washington DC; 2013
116. Clinicaltrials.gov. Efficacy and safety evaluation of Pneumostem versus a control group for treatment of BPD in premature infants, Medipost Co Ltd. Available from: http://clinicaltrials.gov/ct2/show/NCT01828957?term=BPD +pneumostem&rank=1
117. Weichelt U, Cay R, Schmitz T, et al. Prevention of hyperoxia-mediated pulmonary inflammation in neonatal rats by caffeine. Eur Respir J 2013; 41(4): 966-73.
118. Dayanim S, Lopez B, Maisonet TM, et al. Caffeine induces alveolar apoptosis in the hyperoxia-exposed developing mouse lung. Pediatr Res 2014;75:395-402